Regulus Therapeutics reported $-7144000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alnylam Pharmaceuticals ALNY:US $ -181.59M 44.32M
AstraZeneca AZN:LN 292568.43M 24571.33M
Astrazeneca AZN:US $ 3562M 625M
Biogen BIIB:US $ 1075.7M 401M
Celldex Therapeutics CLDX:US $ -20.66M 1.79M
Gilead Sciences GILD:US $ 2585M 837M
GlaxoSmithKline GSK:LN 244700M 1400M
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
Omeros OMER:US $ -37247000 2.48M
Regulus Therapeutics RGLS:US $ -7.14M 0.6M
Sangamo Biosciences SGMO:US $ -42.85M 0.42M
Spectrum Pharmaceuticals SPPI:US $ -25.32M 11.33M
Takeda 4502:JP Y 308798M 158143M
Vital Therapies VTL:US $ -20.59M 0.82M
YTE INCY:US $ 276.8M 132.69M